Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. Lammerts van Bueren JJ, et al. Among authors: peipp m. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. Proc Natl Acad Sci U S A. 2012. PMID: 22431606 Free PMC article. No abstract available.
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S, Klausz K, Albici AM, Ebinger L, Sellmer L, Teipel H, Frenzel A, Langner A, Winterberg D, Krohn S, Hust M, Schirrmann T, Dübel S, Scherließ R, Humpe A, Gramatzki M, Kellner C, Peipp M. Lutz S, et al. Among authors: peipp m. Front Immunol. 2023 Oct 27;14:1227572. doi: 10.3389/fimmu.2023.1227572. eCollection 2023. Front Immunol. 2023. PMID: 37965326 Free PMC article.
Editorial: Effector functions of therapeutic antibodies.
Boross P, Peipp M, Nimmerjahn F. Boross P, et al. Among authors: peipp m. Front Immunol. 2023 Jan 12;13:1126966. doi: 10.3389/fimmu.2022.1126966. eCollection 2022. Front Immunol. 2023. PMID: 36713416 Free PMC article. No abstract available.
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS, Pekar L, Koep K, Lipinski B, Rabinovich B, Evers A, Gehlert CL, Krohn S, Xiao Y, Krah S, Zaynagetdinov R, Toleikis L, Poetzsch S, Peipp M, Zielonka S, Klausz K. Boje AS, et al. Among authors: peipp m. MAbs. 2024 Jan-Dec;16(1):2315640. doi: 10.1080/19420862.2024.2315640. Epub 2024 Feb 19. MAbs. 2024. PMID: 38372053 Free PMC article.
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.
Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S. Bäumer N, et al. Among authors: peipp m. J Hematol Oncol. 2022 Dec 1;15(1):171. doi: 10.1186/s13045-022-01390-5. J Hematol Oncol. 2022. PMID: 36457063 Free PMC article.
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton S, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: peipp m. Blood. 2024 Jun 27;143(26):2735-2748. doi: 10.1182/blood.2023021088. Blood. 2024. PMID: 38518105 Free PMC article.
138 results